Login / Signup

Docosahexaenoic acid in ARSACS: observations in two patients.

Ivana RiccaAlessandra TessaRosanna TrovatoGiacomo Maria BacciFilippo Maria Santorelli
Published in: BMC neurology (2020)
DHA was safe over a long period and well-tolerated by the two patients; both showed a stabilization of clinical symptoms, rather than the expected deterioration, warranting additional investigations in patients with mutations in SACS.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • peritoneal dialysis
  • prognostic factors
  • patient reported outcomes
  • depressive symptoms